Immune Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article HOUSTON, Feb. 17, 2021 /PRNewswire/ --  Vax-Immune Diagnostics announces today it has received CE Mark approval for its first-in-class medical device, LabReady® GBS. LabReady's Group B Strep product is the first in Vax-Immune Diagnostics' lineup of women's health solutions that helps avoid life-threatening complications and expensive consequences for mothers and their babies. With CE Mark approval, LabReady is now available to European physicians, patients, and hospital systems.  The brainchild of Dr. Leonard E. Weisman, renowned neonatologist, LabReady aims to protect...

Andrea -stock.adobe.com Davide Manissero, MD, CMO, Infection and Immune Diagnostics for Qiagen stops by Let’s Talk Medtech to discuss the company’s PCR tests for the COVID-19 variants. The latest chapter in the COVID-19 story involves the variants, VUI 202012/01 (first detected in the United Kingdom), 501Y.V2 (identified in South Africa), and B.1.1.28 P1 (most recently discovered in Brazil). Davide Manissero, MD, CMO, Infection and Immune Diagnostics for Qiagen, talks about the company’s ability to detect these variants that are highly-contagious, in this episo...

QIAGEN N.V.: QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus QIAGEN started cross-checking variants in May 2020 and continues to conduct biweekly assessments QIAseq SARS-CoV-2 Primer Panel helps with sequencing RNA and identifying mutations QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections and will continue to closely monitor their performance as global concerns mount regarding the detection of new viral varian...